Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVO NASDAQ:LSTA NASDAQ:OTLK NASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$3.06-1.0%$3.85$2.82▼$13.13$28.33M-0.6357,970 shs102,002 shsLSTALisata Therapeutics$3.14$4.08$1.81▼$5.07$28.59M0.8130,582 shs1,985 shsOTLKOncobiologics$0.31-6.9%$0.27$0.16▼$3.39$37.46M0.324.90 million shs9.00 million shsSONNSonnet BioTherapeutics$1.02-67.3%$2.37$1.08▼$19.30$7.18M1.482.09 million shs10.08 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed0.00%-11.05%-20.52%-33.91%-64.04%LSTALisata Therapeutics0.00%-0.95%-5.71%-29.91%+25.60%OTLKOncobiologics0.00%+35.86%+8.02%-24.98%-80.99%SONNSonnet BioTherapeutics0.00%0.00%0.00%0.00%-15.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$3.06-1.0%$3.85$2.82▼$13.13$28.33M-0.6357,970 shs102,002 shsLSTALisata Therapeutics$3.14$4.08$1.81▼$5.07$28.59M0.8130,582 shs1,985 shsOTLKOncobiologics$0.31-6.9%$0.27$0.16▼$3.39$37.46M0.324.90 million shs9.00 million shsSONNSonnet BioTherapeutics$1.02-67.3%$2.37$1.08▼$19.30$7.18M1.482.09 million shs10.08 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed0.00%-11.05%-20.52%-33.91%-64.04%LSTALisata Therapeutics0.00%-0.95%-5.71%-29.91%+25.60%OTLKOncobiologics0.00%+35.86%+8.02%-24.98%-80.99%SONNSonnet BioTherapeutics0.00%0.00%0.00%0.00%-15.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVOCervoMed 2.63Moderate Buy$22.60638.56% UpsideLSTALisata Therapeutics 1.67Reduce$15.00377.71% UpsideOTLKOncobiologics 2.00Hold$4.501,352.08% UpsideSONNSonnet BioTherapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SONN, LSTA, CRVO, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026CRVOCervoMed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.005/18/2026LSTALisata Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026OTLKOncobiologics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/15/2026LSTALisata Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/23/2026CRVOCervoMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/22/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.004/21/2026LSTALisata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CRVOCervoMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.003/27/2026OTLKOncobiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/18/2026CRVOCervoMed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $11.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVOCervoMed$4.01M7.07N/AN/A$1.15 per share2.66LSTALisata Therapeutics$170K168.27N/AN/A$1.17 per share2.68OTLKOncobiologics$1.35M27.74N/AN/A($0.24) per share-1.29SONNSonnet BioTherapeutics$1M7.18N/AN/A($0.71) per share-1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVOCervoMed-$26.97M-$3.28N/AN/AN/A-672.80%-136.08%-112.62%N/ALSTALisata Therapeutics-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)OTLKOncobiologics-$62.42M-$1.17N/AN/AN/AN/AN/A-291.28%N/ASONNSonnet BioTherapeutics-$7.44M-$8.05N/AN/AN/AN/A-4,646.10%-342.21%N/ALatest SONN, LSTA, CRVO, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CRVOCervoMed-$0.90-$0.86+$0.04-$0.86$0.07 millionN/A5/15/2026Q2 2026OTLKOncobiologics-$0.12-$0.16-$0.04-$0.05$4.39 million$0.13 million5/11/2026Q1 2026LSTALisata TherapeuticsN/A-$0.50N/A-$0.50N/AN/A3/13/2026Q4 2025CRVOCervoMed-$0.79-$0.88-$0.09-$0.88$0.84 million$0.01 million3/12/2026Q4 2025LSTALisata Therapeutics-$0.74-$0.33+$0.41-$0.33N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVOCervoMedN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVOCervoMedN/A3.364.91LSTALisata TherapeuticsN/A4.234.23OTLKOncobiologicsN/A0.540.28SONNSonnet BioTherapeuticsN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVOCervoMed25.15%LSTALisata Therapeutics8.94%OTLKOncobiologics11.20%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipCRVOCervoMed35.40%LSTALisata Therapeutics9.60%OTLKOncobiologics2.80%SONNSonnet BioTherapeutics8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVOCervoMed49.26 million5.98 millionNot OptionableLSTALisata Therapeutics309.11 million8.23 millionNot OptionableOTLKOncobiologics20120.86 million117.48 millionOptionableSONNSonnet BioTherapeutics107.08 million6.48 millionNot OptionableSONN, LSTA, CRVO, and OTLK HeadlinesRecent News About These CompaniesHyperliquid Strategies Wins Approval to Pursue $1B Offering and HYPE Token TreasuryDecember 3, 2025 | crypto-news-flash.comCHYPE News: Hyperliquid DAT Approval Lifts HYPE Token Nearly 10%December 3, 2025 | livebitcoinnews.comLHyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business CombinationDecember 2, 2025 | globenewswire.comSonnet BioTherapeutics stockholders approve Hyperliquid Strategies combinationDecember 2, 2025 | msn.comSonnet shareholders approve Hyperliquid merger to launch HYPE-focused crypto treasuryDecember 2, 2025 | cryptobriefing.comCHYPE Jumps 10% as Hyperliquid Treasury Firm Sonnet Secures Merger ApprovalDecember 2, 2025 | coingape.comCSonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies IncDecember 2, 2025 | finance.yahoo.comSonnet delays vote on Hyperliquid merger to launch $1B HYPE-focused treasury firmNovember 18, 2025 | cryptobriefing.comCSonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special MeetingNovember 18, 2025 | globenewswire.comSonnet BioTherapeutics Announces Special Meeting for Business Combination VoteOctober 29, 2025 | msn.comHyperliquid Price Surges as $1B Fundraising and IPO Plans Boost HYPEOctober 25, 2025 | thecurrencyanalytics.comTHyperliquid Strategies Aims to Raise $1 Billion to Expand HYPE Token TreasuryOctober 24, 2025 | thecurrencyanalytics.comTHyperliquid Token Defies Market Slump as Institutional Capital Flows InOctober 24, 2025 | thecurrencyanalytics.comTHyperliquid Price Soars 12% As Hyperliquid Strategies Plans $1B Raise For HYPE TreasuryOctober 23, 2025 | insidebitcoins.comIHyperliquid's $1B Power Play: HYPE Token Surge and Bitcoin Whale FrenzyOctober 23, 2025 | econotimes.comHyperliquid Strategies Files $1B IPO to Build HYPE TreasuryOctober 23, 2025 | financefeeds.comFHyperliquid’s HYPE soars as Wall Street backs $888 million mergerOctober 23, 2025 | msn.comHyperliquid Wants $1B to Power Its Next HYPE Token ExpansionOctober 23, 2025 | finance.yahoo.comSonnet BioTherapeutics, Spanios collaborate on non-clinical study of SON-1010October 16, 2025 | msn.comEvaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with SarcomaOctober 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSONN, LSTA, CRVO, and OTLK Company DescriptionsCervoMed NASDAQ:CRVO$3.06 -0.03 (-0.97%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.14 +0.08 (+2.61%) As of 05/22/2026 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Lisata Therapeutics NASDAQ:LSTA$3.14 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.16 +0.01 (+0.48%) As of 05/22/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Oncobiologics NASDAQ:OTLK$0.31 -0.02 (-6.94%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.32 +0.01 (+2.29%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Sonnet BioTherapeutics NASDAQ:SONNSonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
